Previous 10 | Next 10 |
2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...
2024-06-30 20:30:56 ET Rounding out the top five were Moderna ( NASDAQ: MRNA ) and Novo Nordisk ( NVO ) with gains of, respectively, ~12.5% and ~11.9% .... Read the full article on Seeking Alpha For further details see: Alnylam, Lilly, AstraZeneca among best ...
2024-06-29 15:44:55 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End ...
2024-06-24 13:00:04 ET Michael Yee from Jefferies issued a price target of $85.00 for GILD on 2024-06-24 10:57:00. The adjusted price target was set to $85.00. At the time of the announcement, GILD was trading at $71.24. The overall price target consensus is at $80.71 wi...
2024-06-24 12:30:03 ET Jefferies analyst issues BUY recommendation for GILD on June 24, 2024 10:57AM ET. The previous analyst recommendation was Buy. GILD was trading at $71.235 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...
2024-06-24 09:41:40 ET Summary Gilead Sciences reported positive Phase 3 data for lenacapavir, a biannual HIV PrEP therapy, leading to a 12% stock boost. Q1 earnings showed growth in HIV product sales, with Trodelvy's notable 39% increase, and total revenue beating estimates by $3...
2024-06-23 12:49:01 ET More on the markets SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation Perfect Time For November Election Protection S&P posts three-week win streak, but momentum stalls after hitting 5,500 points mark ...
2024-06-23 09:01:47 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-06-22 03:56:43 ET Summary Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revolutionize HIV prevention and treatment, leading to mar...
2024-06-21 09:06:00 ET U.S. stock index futures on Friday pointed to a marginally lower open, a day after Wall Street's rally stalled following another historic milestone. Here are some stocks to watch on Friday: ... Read the full article on Seeking Alpha For further de...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...